Physiologically-based pharmacokinetic modeling of belimumab for systemic lupus erythematosus patients to predict the withdrawal time in pregnancy and vaccine time in infants
{{output}}
Belimumab (BEL) is a monoclonal antibody that targets B cell activating factor (BAFF) and has been approved for treating systemic lupus erythematosus (SLE). However, its optimal withdrawal time during pregnancy and the appropriate vaccine timing for infants re... ...
